Cognition Therapeutics (CGTX) EPS (Weighted Average and Diluted) (2020 - 2026)
Cognition Therapeutics (CGTX) reported EPS (Weighted Average and Diluted) of -$0.05 for Q1 2026, up 64.29% year-over-year from -$0.03 in Q1 2025, and down 150.0% on a QoQ basis from -$0.02 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.05 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 64.29% year-over-year to -$0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.24 (up 67.57% YoY) and the FY2025 annual result came in at -$0.32, up 62.79% from the prior year.
- EPS (Weighted Average and Diluted) retreated to -$0.05 in Q1 2026 per CGTX's latest filing, from -$0.02 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.02 in Q4 2025 and bottomed at -$0.29 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.18 (2024), against an average of -$0.18.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 96.43% in 2022, while the deepest fall reached 101.7% in 2022.
- Tracing CGTX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.2 in 2022, then tumbled by 35.0% to -$0.27 in 2023, then soared by 37.04% to -$0.17 in 2024, then jumped by 88.24% to -$0.02 in 2025, then slumped by 150.0% to -$0.05 in 2026.
- Per Business Quant, the three latest CGTX EPS (Weighted Average and Diluted) figures stand at -$0.05 (Q1 2026), -$0.02 (Q4 2025), and -$0.06 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 4.02 |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 6.75 |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 1.51 |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | -0.02 |
| Sep 30, 2025 | -0.06 |
| Jun 30, 2025 | -0.11 |
| Mar 31, 2025 | -0.14 |
| Dec 31, 2024 | -0.17 |
| Sep 30, 2024 | -0.25 |
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | -0.27 |
| Dec 31, 2023 | -0.27 |
| Sep 30, 2023 | -0.22 |
| Jun 30, 2023 | -0.16 |
| Mar 31, 2023 | -0.21 |
| Dec 31, 2022 | -0.20 |
| Sep 30, 2022 | -0.29 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.17 |
| Dec 31, 2021 | 11.74 |
| Sep 30, 2021 | -8.12 |
| Jun 30, 2021 | -4.77 |
| Mar 31, 2021 | -1.64 |
| Dec 31, 2020 | -5.42 |
| Sep 30, 2020 | -5.31 |